🔎 Trials Near Me

Utama › Leukemia Mieloid Akut › Washington › Spokane

Kajian klinikal Leukemia Mieloid Akut di Spokane, WA

4 kajian untuk Leukemia Mieloid Akut sedang mencari peserta di lokasi dalam dan sekitar Spokane (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
  • Cancer Care Northwest - Spokane South, Spokane
  • Cancer Care Northwest-Valley, Spokane
  • Cancer Care Northwest-North Spokane, Spokane
Umur 40 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05334069

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Mengambil pesertaFasa 3
  • Providence Sacred Heart Medical Center and Children's Hospital, Spokane
6 Months – 21 Years · Semua jantina · Dikemas kini 17 Sep 2026 · NCT04293562

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

Mengambil pesertaFasa 3
  • Providence Sacred Heart Medical Center and Children's Hospital, Spokane
Umur 1 hingga 25 · Semua jantina · Dikemas kini 4 Sep 2026 · NCT07022678

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Mengambil pesertaFasa 1/2
  • Providence Sacred Heart Medical Center and Children's Hospital, Spokane
Sehingga umur 22 · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT04726241

Kajian Leukemia Mieloid Akut di bandar lain

Kajian lain di Spokane

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.